Ocular Therapeutix, Inc. (OCUL): Price and Financial Metrics

Ocular Therapeutix, Inc. (OCUL): $13.79

-0.14 (-1.01%)

POWR Rating

Component Grades













Add OCUL to Watchlist
Sign Up

Industry: Biotech


of 486

in industry


  • Growth is the dimension where OCUL ranks best; there it ranks ahead of 64.17% of US stocks.
  • OCUL's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
  • OCUL's current lowest rank is in the Stability metric (where it is better than 4.43% of US stocks).

OCUL Stock Summary

  • With a price/sales ratio of 48.01, Ocular Therapeutix Inc has a higher such ratio than 94.31% of stocks in our set.
  • Revenue growth over the past 12 months for Ocular Therapeutix Inc comes in at 248.93%, a number that bests 97.24% of the US stocks we're tracking.
  • Ocular Therapeutix Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -20.14%, greater than the shareholder yield of just 12.6% of stocks in our set.
  • Stocks that are quantitatively similar to OCUL, based on their financial statements, market capitalization, and price volatility, are PIPR, GIGA, GTLS, GNCA, and SONO.
  • Visit OCUL's SEC page to see the company's official filings. To visit the company's web site, go to www.ocutx.com.

OCUL Price Target

For more insight on analysts targets of OCUL, see our OCUL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $25.33 Average Broker Recommendation 1.5 (Moderate Buy)

OCUL Stock Price Chart Interactive Chart >

Price chart for OCUL

OCUL Price/Volume Stats

Current price $13.79 52-week high $24.30
Prev. close $13.93 52-week low $7.14
Day low $13.54 Volume 495,900
Day high $13.96 Avg. volume 1,035,385
50-day MA $15.09 Dividend yield N/A
200-day MA $15.74 Market Cap 1.05B

Ocular Therapeutix, Inc. (OCUL) Company Bio

Ocular Therapeutix is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. The company was founded in 2006 and is based in Bedford, Massachusetts.

OCUL Latest News Stream

Event/Time News Detail
Loading, please wait...

OCUL Latest Social Stream

Loading social stream, please wait...

View Full OCUL Social Stream

Latest OCUL News From Around the Web

Below are the latest news stories about Ocular Therapeutix Inc that investors may wish to consider to help them evaluate OCUL as an investment opportunity.

Implied Volatility Surging for Ocular Therapeutix (OCUL) Stock Options

Investors need to pay close attention to Ocular Therapeutix (OCUL) stock based on the movements in the options market lately.

Yahoo | May 20, 2021

Ocular Therapeutix™ Reports First Quarter 2021 Financial Results and Business Update

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the first quarter of 2021, and provided updates on its strong ophthalmology pipeline.

Yahoo | May 5, 2021

Ocular Therapeutix, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 5, 2021 / Ocular Therapeutix, Inc. (NASDAQ:OCUL) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 5, 2021 at 4:30 PM Eastern Time.

Yahoo | May 5, 2021

CORRECTING and REPLACING Ocular Therapeutix™ To Present Pre-Clinical and Clinical Data at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Please replace the release dated April 29, 2021, with the following corrected version due to multiple revisions.

Yahoo | May 3, 2021

Ocular Therapeutix™ Fulfills Post-Marketing Approval Requirements for ReSure® Sealant

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, has received notification from the U.S. Food and Drug Administration (FDA) confirming it has fulfilled all post-approval study requirements for ReSure® Sealant, with a requirement to update the ReSure label reflecting the study results. As a condition for ReSure’s pre-market approval application (PMA) in 2014, the FDA required two post-approval studies to be completed. The first, referred to as the Clinical Post-Approval Study, was completed in 2016. This notification marks the completion of the second, the Device Exposure Registry Study, a retrospective analysis comparing endophthalmitis rates ...

Yahoo | May 3, 2021

Read More 'OCUL' Stories Here

OCUL Price Returns

1-mo -1.64%
3-mo -23.52%
6-mo N/A
1-year 56.70%
3-year 77.36%
5-year 166.73%
YTD -33.38%
2020 424.05%
2019 -0.75%
2018 -10.56%
2017 -46.83%
2016 -10.67%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.9279 seconds.